Developing and commercializing first-in-class, well-characterized drugs for life-threatening, rare and ultra-rare diseases with high unmet medical needs and no approved therapies.

Eiger BioPharmaceuticals to Host Conference Call for Third Quarter 2021 Financial Results and Business Update on Thursday, November 4

- Live Conference Call and Webcast at 4:30 PM ET - PALO ALTO, Calif. , Oct. 21, 2021 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc.  (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare

Eiger BioPharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

PALO ALTO, Calif. , Oct. 1, 2021 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today reported that, in connection with the

Eiger BioPharmaceuticals Appoints Erik Atkisson as General Counsel and Chief Compliance Officer

PALO ALTO, Calif. , Sept. 21, 2021 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced the appointment of Erik